CardioMEMS
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | $2.5m | Series A | |
$14.0m | Series B | ||
N/A | $16.0m | Series C | |
$22.6m | Series D | ||
N/A | $23.3m | Series D | |
$33.0m | Series E | ||
N/A | $1.2m | Debt | |
$22.1m | Series F | ||
N/A | $37.9m | Early VC | |
$60.0m | Growth Equity VC | ||
$455m Valuation: $455m | Acquisition | ||
Total Funding | €210m |
Recent News about CardioMEMS
EditAbbott's cardiovascular division specializes in developing advanced medical devices and technologies aimed at improving patient care in the cardiovascular field. The company serves healthcare professionals and institutions by providing a wide range of products, including stents, heart valves, and remote monitoring systems for chronic heart failure patients. Operating in the global healthcare market, Abbott leverages its extensive research and development capabilities to innovate and bring effective solutions to market. The business model revolves around the sale of these medical devices and associated services, generating revenue through direct sales to hospitals and healthcare providers, as well as through ongoing support and maintenance contracts. Abbott's cardiovascular products are designed to meet the needs of physicians and patients, ensuring better health outcomes and streamlined medical procedures.
Keywords: cardiovascular devices, patient care, medical technology, stents, heart valves, remote monitoring, chronic heart failure, healthcare professionals, global market, innovation.